HIGHLIGHTS
- who: Cristina Birzu and collaborators from the Department of Neurology, Erasmus University Medical Center, Doctor Molewaterplein , have published the research work: Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives, in the Journal: Cancers 2021, 13, 47. of /2021/
- what: The study was negative in the primary efficacy analysis, with a median follow-up of 15.0 months; however, the combination arm showed a trend for longer survival compared to standard treatment (HR=0.71; 95% CI, 0.50-1.02; p=0.062).
- how: Perifosine (PRF) an oral alkylphospholipid with an antineoplastic . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.